Stephen H. Barnes Sells 5,640 Shares of Accolade, Inc. (NASDAQ:ACCD) Stock

Accolade, Inc. (NASDAQ:ACCD) CFO Stephen H. Barnes sold 5,640 shares of Accolade stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total transaction of $20,304.00. Following the sale, the chief financial officer now owns 219,623 shares in the company, valued at approximately $790,642.80. This trade represents a 2.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Accolade Price Performance

Shares of ACCD opened at $3.54 on Friday. The stock has a market cap of $285.10 million, a P/E ratio of -3.44 and a beta of 2.07. Accolade, Inc. has a 1 year low of $3.08 and a 1 year high of $15.36. The stock’s 50-day moving average price is $3.59 and its two-hundred day moving average price is $4.36. The company has a current ratio of 2.72, a quick ratio of 2.72 and a debt-to-equity ratio of 0.49.

Accolade (NASDAQ:ACCD) last released its quarterly earnings data on Tuesday, October 8th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.14. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. The business had revenue of $106.40 million for the quarter, compared to analyst estimates of $104.87 million. During the same quarter last year, the firm earned ($0.43) EPS. Accolade’s quarterly revenue was up 9.8% compared to the same quarter last year. On average, equities analysts predict that Accolade, Inc. will post -0.92 earnings per share for the current year.

Institutional Trading of Accolade

Large investors have recently made changes to their positions in the company. Clearline Capital LP bought a new position in Accolade during the second quarter worth about $2,974,000. Whetstone Capital Advisors LLC bought a new stake in Accolade during the 3rd quarter worth approximately $3,842,000. Cubist Systematic Strategies LLC raised its holdings in shares of Accolade by 273.4% during the second quarter. Cubist Systematic Strategies LLC now owns 260,040 shares of the company’s stock worth $931,000 after acquiring an additional 190,396 shares during the period. Acadian Asset Management LLC acquired a new position in Accolade in the 2nd quarter worth $1,229,000. Finally, Johnson Financial Group LLC bought a new position in Accolade during the 3rd quarter worth about $1,642,000. Institutional investors own 84.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ACCD shares. Barclays dropped their price objective on shares of Accolade from $5.50 to $5.00 and set an “equal weight” rating for the company in a report on Wednesday, October 9th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Accolade in a research report on Monday, October 7th. Wells Fargo & Company decreased their target price on Accolade from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Friday, October 11th. Truist Financial cut their price target on Accolade from $9.00 to $7.50 and set a “buy” rating for the company in a report on Wednesday, October 9th. Finally, Stephens lowered their price objective on shares of Accolade from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, October 9th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.04.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.